Get the Stockscreener App
3.74
3.11%
-0.12
After Hours:
3.74
Whitehawk Therapeutics Inc stock is traded at $3.74, with a volume of 166.93K.
It is down -3.11% in the last 24 hours and down -26.38% over the past month.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
See More
Previous Close:
$3.86
Open:
$3.85
24h Volume:
166.93K
Relative Volume:
0.36
Market Cap:
$213.21M
Revenue:
$7.15M
Net Income/Loss:
$-20.60M
P/E Ratio:
7.8803
EPS:
0.4746
Net Cash Flow:
$-97.99M
1W Performance:
-10.95%
1M Performance:
-26.38%
6M Performance:
+4.18%
1Y Performance:
+97.88%
1-Day Range:
$3.74
$3.89
1-Week Range:
$3.74
$4.20
52-Week Range:
$1.82
$5.495
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
Name
Whitehawk Therapeutics Inc
Sector
Industry
Phone
551-321-2234
Address
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
3.74 | 213.21M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | Oppenheimer | Outperform |
| Aug-27-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-21-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-21-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
View All
Whitehawk Therapeutics Inc Stock (WHWK) Latest News
Insiders At Whitehawk Therapeutics Sold US$2.5m In Stock, Alluding To Potential Weakness - simplywall.st
WHWK News | WHITEHAWK THERAPEUTICS INC (NASDAQ:WHWK) - ChartMill
WHWK - Finviz
Whitehawk Therapeutics, Inc.(NasdaqCM: WHWK) added to S&P Global BMI Index - marketscreener.com
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know - Eastern Progress
Whitehawk (WHWK) clarifies CSO RSU vesting terms - Stock Titan
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Short Interest Update - MarketBeat
Whitehawk Therapeutics advances next-gen ADC ca... - pluang.com
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 - The Journal Gazette
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Whitehawk Therapeutics Adds Oncology Leader to Board - The Globe and Mail
Whitehawk Therapeutics appoints Vijay Iyengar to board By Investing.com - Investing.com South Africa
Oncology veteran Vijay Iyengar joins Whitehawk Therapeutics (WHWK) board - Stock Titan
Whitehawk Therapeutics appoints Vijay Iyengar to board - investing.com
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, To Board Of Directors - TradingView
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors - PR Newswire
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise - Stocktwits
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) Stock Price, News & Analysis - Kalkine
BlackRock Inc. Makes New $8.81 Million Investment in Whitehawk Therapeutics, Inc. $WHWK - marketbeat.com
WHWK Q2 2026 Earnings: Narrower Loss Beats Estimates by 33.73%, Stock Slips 1.7%Margin Guidance - dars.gov.et
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences - PR Newswire
Montanova Capital LLC Has $19.69 Million Position in Whitehawk Therapeutics, Inc. $WHWK - MarketBeat
WHWK Q2 2026 Earnings: 33.7% EPS Surprise Highlights Cost Discipline Despite Share SlipEarnings Season Preview - careplusvn.com
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now? - Yahoo Finance
WHWK | Whitehawk Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Whitehawk (WHWK) Shares: Finishes 2.31% Up at $4.87 on the Day; Next Test: the $4.63 to $5.11 Range Remains in FocusCall Resistance - vinanet.vn
Whitehawk (WHWK) Watch: Gains 2.94% to Reach $4.90 in the Latest Session; Range Check: $4.66 and $5.15 Define the Nearby Reference Levels at the CloseRetail Driven Moves - Vinanet
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
WHWK Q2 2026 Earnings: Narrower-than-Expected Loss Beats Estimates, Shares Rise 4.04%Net Profit Margin - vinanet.vn
WHWK Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 33.73% EPS Surprise, Shares Rise 4.04% - vinanet.vn
Whitehawk Therapeutics (WHWK) Jumps 4.5% to $4.66, Edges Toward Key ResistanceBackspread Trade - vinanet.vn
Whitehawk Therapeutics (WHWK) Drops 4.7% to $4.46, Approaches Key Support at $4.24Diagonal Spread Trade - vinanet.vn
Whitehawk Therapeutics (WHWK): OrbiMed entities disclose 3.93M-share, 7.3% ownership stake - Stock Titan
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform - Yahoo Finance
WHWK Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineEarnings Season Preview - careplusvn.com
Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
JonesTrading Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Aadi Bioscience Inc (3350.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Whitehawk Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Whitehawk Therapeutics 2Q 2026: Revenue $0 Net loss $16.64M, EPS $(0.20) — 10-Q Summary - tradingview.com
Whitehawk Therapeutics reports Q2 2026 net loss $16.6M; cash $190.0M funds into 2H 2028 - TradingView
Whitehawk Therapeutics reports $16.6 million Q2 loss as trials advance - Quiver Quantitative
Whitehawk Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Whitehawk Therapeutics 2Q Loss/Shr 20c >WHWK - Moomoo
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - PR Newswire
Whitehawk Therapeutics (WHWK) Slips 1.7% as Shares Hover Between Support and ResistanceWave Extension - dars.gov.et
Akari Therapeutics Highlights WhiteHawk Collaboration and Dual-Payload ADC Strategy in CEO Corner Segment - Quiver Quantitative
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation - Yahoo Finance
WHWK Q1 2026 Earnings: Narrower-than-Expected Loss Points to Cost DisciplineGuidance Update - vinanet.vn
Whitehawk Therapeutics Inc Stock (WHWK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):